Want to see IN:AJANTPHARM full AI Analyst Report?

Ajanta Pharma Limited (AJANTPHARM) Price & Analysis

6 Followers

AJANTPHARM Stock Chart & Stats

₹2920.85

-₹25.05(-0.84%)

At close: Jan 09 4:00 PM EST

₹2920.85

-₹25.05(-0.84%)

Day’s Range― - ―

52-Week Range₹2,335.00 - ₹3,476.70

Previous CloseN/A

Volume47.67K

Average Volume (3M)2.10K

Market Cap

₹427.62B

Enterprise Value₹386.28B

Total Cash (Recent Filing)₹9.40B

Total Debt (Recent Filing)₹2.46B

Price to Earnings (P/E)40.5

Beta0.34

Next Earnings

Jul 23, 2026

EPS Estimate

25.1

Next Dividend Ex-DateN/A

Dividend Yield1.04%

Share Statistics

EPS (TTM)77.91

Shares Outstanding124,935,620

10 Day Avg. Volume2,991

30 Day Avg. Volume2,099

Financial Highlights & Ratios

PEG Ratio2.23

Price to Book (P/B)7.74

Price to Sales (P/S)6.43

P/FCF Ratio231.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)98.75

Revenue Forecast (FY)₹62.43B

Bulls Say, Bears Say

Bulls Say

Diversified Sales Channels And International PresenceAjanta's branded-generics model spans domestic prescription-led sales and international markets via owned front-ends and distributor partners. That geographic and channel diversification, plus in-house formulation manufacturing, supports stable demand, lowers single-market dependency and aids scalable growth over years.

Consistent Revenue Growth And Solid Historical MarginsSteady revenue expansion (FY2026 ~11% YoY) alongside historically strong net margins (~19–23%) indicates persistent product demand and pricing power in core franchises. Durable top-line growth with healthy margins underpins reinvestment capacity and long-run profitability resilience.

Conservative Balance Sheet And Strong ROELow leverage and expanding equity give Ajanta significant financial flexibility. Consistent ROE in the high-teens/low-20s signals efficient capital allocation and profit generation, enabling sustained investment in brands, R&D and international expansion without overreliance on external financing.

Bears Say

Volatile Cash Conversion And Weaker FY2026 Free Cash FlowOperating cash flow underperforming net income and a sharp FCF decline in FY2026 indicate working-capital swings or higher cash investments. This volatility reduces predictability of cash available for dividends, buybacks or capex, raising execution risk for strategic plans over the medium term.

Margin Compression In FY2026 (gross Margin Drop)A marked drop in gross margin in FY2026 signals pressure from costs, mix shifts or pricing dynamics. If structural, sustained margin erosion would reduce operating leverage, constrain reinvestment and weaken long-term returns even if revenues continue growing.

Uptick In Debt Amid Historically Low LeverageAn increase in debt in FY2026, even from a low base, reduces the margin of safety afforded by a conservative balance sheet. Continued debt growth could raise interest costs and limit flexibility for acquisitions or capital spending, increasing financial risk over the medium term.

Ajanta Pharma Limited News

Ajanta Pharma Sets July 2026 Virtual AGM, Releases FY 2025-26 Reports

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has issued an update. Ajanta Pharma has scheduled its forty-seventh Annual General...

14d ago

Ajanta Pharma Receives US FDA Form 483 With Five Observations at Paithan Plant

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an announcement. Ajanta Pharma has announced that the U.S. Food...

2M ago

Ajanta Pharma Denies Involvement in Rumoured Restaurant Brands Asia Acquisition

An update from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma has issued a formal...

5M ago

Ajanta Pharma Publishes Q3 and Nine-Month FY26 Results in Newspapers in Line with SEBI Norms

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has shared an update. Ajanta Pharma Limited has notified the stock exchanges...

5M ago

Ajanta Pharma to Engage Investors at Multiple February 2026 Conferences

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) just unveiled an update. Ajanta Pharma has announced its participation in multiple...

5M ago

Ajanta Pharma to Consider Interim Dividend Declaration

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

8M ago

Ajanta Pharma to Consider Interim Dividend for FY 2026

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

8M ago

Ajanta Pharma Reports Strong Q1 FY 2026 Financial Results

An update from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma Limited reported a robust...

11M ago

AJANTPHARM FAQ

What was Ajanta Pharma Limited’s price range in the past 12 months?

Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3476.70 in the past 12 months.

What is Ajanta Pharma Limited’s market cap?

Ajanta Pharma Limited’s market cap is ₹427.62B.

When is Ajanta Pharma Limited’s upcoming earnings report date?

Ajanta Pharma Limited’s upcoming earnings report date is Jul 23, 2026 which is in 21 days.

How were Ajanta Pharma Limited’s earnings last quarter?

Ajanta Pharma Limited released its earnings results on May 05, 2026. The company reported ₹21.3 earnings per share for the quarter, beating the consensus estimate of ₹20.13 by ₹1.17.

Is Ajanta Pharma Limited overvalued?

According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ajanta Pharma Limited pay dividends?

Ajanta Pharma Limited pays a Annually dividend of ₹28 which represents an annual dividend yield of 1.04%. See more information on Ajanta Pharma Limited dividends here

What is Ajanta Pharma Limited’s EPS estimate?

Ajanta Pharma Limited’s EPS estimate is 25.1.

How many shares outstanding does Ajanta Pharma Limited have?

Ajanta Pharma Limited has 124,935,620 shares outstanding.

What happened to Ajanta Pharma Limited’s price movement after its last earnings report?

Ajanta Pharma Limited reported an EPS of ₹21.3 in its last earnings report, beating expectations of ₹20.13. Following the earnings report the stock price went down -0.112%.

Which hedge fund is a major shareholder of Ajanta Pharma Limited?

Currently, no hedge funds are holding shares in IN:AJANTPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ajanta Pharma Limited

Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.